Royalty Pharma: Again, Guidance Raised, Buy Confirmed

Core Viewpoint - Royalty Pharma plc has demonstrated strong performance with double-digit sales growth, marking a positive start to the earnings season for the company [1]. Group 1: Financial Performance - The company reported positive results for Q4 and FY 2024, indicating robust financial health and growth potential [1]. Group 2: Market Position - Royalty Pharma is actively engaging with buy-side hedge professionals who focus on fundamental, income-oriented, long-term analysis across various sectors in developed markets [1].